BioProtocol is an innovative platform in the realm of Decentralized Science (DeSci), dedicated to funding and commercializing scientific research in the biotechnology sector. Through this protocol, global patients, scientists, and biotech investors can collectively fund, create, and own tokenized biotech projects and intellectual property (IP), thereby accelerating advancements in biotechnology.

BioProtocol aims to address numerous pain points in traditional scientific funding and biotech commercialization, including lengthy funding processes, the "valley of death" for early-stage research, centralized funding, IP barriers, and insufficient patient involvement. By leveraging decentralized funding models, capital efficiency, global resource integration, and shared IP, BioProtocol is infusing new vitality into biotechnological innovation.

The success of BioProtocol is driven by a highly skilled and passionate team:

• Paul Kohlhaas: A tokenomics expert and one of the main drivers behind BioProtocol's innovative funding mechanisms.

• James Sinka: Focused on research and development, as well as building a strong community of supporters and participants.

• Jose Pinto: Legal advisor, ensuring compliance and smooth operations within the complex regulatory environment.

• Leonard Boltz: Product expert, responsible for creating user-friendly tools to bring BioProtocol's vision to life.

• Clemens Ortlepp: Product lead, working with Leonard Boltz to refine BioProtocol's offerings.

BioProtocol has completed multiple rounds of private and public fundraising:

• Private Financing:

  • Pre-Seed Round: Raised $900,000 with a valuation of approximately $35 million.

  • Seed Round: Raised $1.4 million with a valuation of approximately $69 million.

• Public Financing:

  • Genesis Round 1: Raised $6.2 million with a valuation of approximately $85 million.

  • Genesis Round 2: Raised $18.2 million with a valuation of approximately $142 million.

  • Genesis Round 2.5: Raised $3.5 million with a valuation of approximately $219 million.

1. Governance Token (BIO):

   • Standard: ERC-20

   • Total Supply: 3,320,000,000 tokens

   • Allocation:

     • Team: 21.20%

     • Advisors: 4.70%

     • Private Investors: 13.60%

     • Community Auction: 20.00%

     • Community Airdrop: 6.00%

     • Ecosystem Incentives: 19.00%

     • Liquidity & Marketing: 2.50%

2. Token Functions:

   • Governance Rights: BIO holders can participate in protocol governance, including meta-governance of BioDAO.

   • Whitelist Access: BIO holders gain priority access to BioDAO funding rounds and investment opportunities in tokenized IPs.

   • Curation Management: BIO holders decide which BioDAO projects can launch via the BIO Launchpad.

   • Protocol Liquidity: BIO Protocol provides liquidity using BioDAO and IP tokens from its treasury, earning trading fees.

1. BIO Launchpad:

   • A core feature of BioProtocol, BIO Launchpad operates in three phases:

     • Governance Phase: BIO holders vote on which BioDAO projects can launch via BioProtocol.

     • Acceleration Phase: Projects raise their first funds through auctions or bonding curve mechanisms.

     • Detachment Phase: Projects enter the open market via on-chain liquidity pools, with liquidity support from BioProtocol.

2. BioDAO Launchpad:

   • BioProtocol supports the creation and development of BioDAOs, assisting with legal governance frameworks, branding, and Web3 tool deployment. BIO collaborates with Catalyst and Pump.science to provide funding and AI tools for BioDAOs.

3. Liquidity Protocol:

   • BioProtocol offers deep on-chain liquidity pools, supporting liquidity trading between BioDAO tokens and ETH, promoting the healthy development of the DeSci ecosystem.

4. Tokenized Intellectual Property:

   • BioProtocol tokenizes scientific IP, providing liquidity and enabling investors to participate in the value creation of biotech assets at an earlier stage.

As an innovative project in the DeSci space, BioProtocol not only offers new funding and incentive mechanisms for global scientific research but also achieves transparent capital flow and decentralized resource sharing through blockchain technology. The four core components of BioProtocol—BioDAO, Curation, Bio/Acc Rewards, and IP Tokens—form an innovative and efficient scientific research ecosystem, providing new opportunities for collaboration and development for researchers worldwide.

BioProtocol is a project with disruptive potential, offering new possibilities for scientific research and biotech commercialization, as well as opportunities for global investors to participate in cutting-edge scientific endeavors.

BioProtocol is an innovative platform in the realm of Decentralized Science (DeSci), dedicated to funding and commercializing scientific research in the biotechnology sector. Through this protocol, global patients, scientists, and biotech investors can collectively fund, create, and own tokenized biotech projects and intellectual property (IP), thereby accelerating advancements in biotechnology.

BioProtocol aims to address numerous pain points in traditional scientific funding and biotech commercialization, including lengthy funding processes, the "valley of death" for early-stage research, centralized funding, IP barriers, and insufficient patient involvement. By leveraging decentralized funding models, capital efficiency, global resource integration, and shared IP, BioProtocol is infusing new vitality into biotechnological innovation.

The success of BioProtocol is driven by a highly skilled and passionate team:

• Paul Kohlhaas: A tokenomics expert and one of the main drivers behind BioProtocol's innovative funding mechanisms.

• James Sinka: Focused on research and development, as well as building a strong community of supporters and participants.

• Jose Pinto: Legal advisor, ensuring compliance and smooth operations within the complex regulatory environment.

• Leonard Boltz: Product expert, responsible for creating user-friendly tools to bring BioProtocol's vision to life.

• Clemens Ortlepp: Product lead, working with Leonard Boltz to refine BioProtocol's offerings.

BioProtocol has completed multiple rounds of private and public fundraising:

• Private Financing:

  • Pre-Seed Round: Raised $900,000 with a valuation of approximately $35 million.

  • Seed Round: Raised $1.4 million with a valuation of approximately $69 million.

• Public Financing:

  • Genesis Round 1: Raised $6.2 million with a valuation of approximately $85 million.

  • Genesis Round 2: Raised $18.2 million with a valuation of approximately $142 million.

  • Genesis Round 2.5: Raised $3.5 million with a valuation of approximately $219 million.

1. Governance Token (BIO):

   • Standard: ERC-20

   • Total Supply: 3,320,000,000 tokens

   • Allocation:

     • Team: 21.20%

     • Advisors: 4.70%

     • Private Investors: 13.60%

     • Community Auction: 20.00%

     • Community Airdrop: 6.00%

     • Ecosystem Incentives: 19.00%

     • Liquidity & Marketing: 2.50%

2. Token Functions:

   • Governance Rights: BIO holders can participate in protocol governance, including meta-governance of BioDAO.

   • Whitelist Access: BIO holders gain priority access to BioDAO funding rounds and investment opportunities in tokenized IPs.

   • Curation Management: BIO holders decide which BioDAO projects can launch via the BIO Launchpad.

   • Protocol Liquidity: BIO Protocol provides liquidity using BioDAO and IP tokens from its treasury, earning trading fees.

1. BIO Launchpad:

   • A core feature of BioProtocol, BIO Launchpad operates in three phases:

     • Governance Phase: BIO holders vote on which BioDAO projects can launch via BioProtocol.

     • Acceleration Phase: Projects raise their first funds through auctions or bonding curve mechanisms.

     • Detachment Phase: Projects enter the open market via on-chain liquidity pools, with liquidity support from BioProtocol.

2. BioDAO Launchpad:

   • BioProtocol supports the creation and development of BioDAOs, assisting with legal governance frameworks, branding, and Web3 tool deployment. BIO collaborates with Catalyst and Pump.science to provide funding and AI tools for BioDAOs.

3. Liquidity Protocol:

   • BioProtocol offers deep on-chain liquidity pools, supporting liquidity trading between BioDAO tokens and ETH, promoting the healthy development of the DeSci ecosystem.

4. Tokenized Intellectual Property:

   • BioProtocol tokenizes scientific IP, providing liquidity and enabling investors to participate in the value creation of biotech assets at an earlier stage.

As an innovative project in the DeSci space, BioProtocol not only offers new funding and incentive mechanisms for global scientific research but also achieves transparent capital flow and decentralized resource sharing through blockchain technology. The four core components of BioProtocol—BioDAO, Curation, Bio/Acc Rewards, and IP Tokens—form an innovative and efficient scientific research ecosystem, providing new opportunities for collaboration and development for researchers worldwide.

BioProtocol is a project with disruptive potential, offering new possibilities for scientific research and biotech commercialization, as well as opportunities for global investors to participate in cutting-edge scientific endeavors.